ALSA and ALSTDI Convene ALS Biomarker Meeting

The ALS Association and ALS Therapy Development Institute convened 24 leaders from academia, government and the pharmaceutical and biotechnology industries to identify approaches to accelerating biomarker development for ALS. Areas identified as particularly important for cooperation were standardized collection of biospecimens and harmonization of data collection methods during clinical trials. Another discussion point was the different type of ALS biomarkers and their distinct applications: biomarkers for distinguishing different subtypes of ALS could help in patient selection for clinical trials, while biomarkers for target engagement would help determine whether a drug is reaching its target and affecting the desired disease pathway. Prize4Life’s contributions to the efforts to identify biomarkers through the $1M ALS Biomarker Prize were also mentioned.

The ALS Association and ALS Therapy Development Institute convened 24 leaders from academia, government and the pharmaceutical and biotechnology industries to identify approaches to accelerating biomarker development for ALS. Areas identified as particularly important for cooperation were standardized collection of biospecimens and harmonization of data collection methods during clinical trials. Another discussion point was the different type of ALS biomarkers and their distinct applications: biomarkers for distinguishing different subtypes of ALS could help in patient selection for clinical trials, while biomarkers for target engagement would help determine whether a drug is reaching its target and affecting the desired disease pathway. Prize4Life’s contributions to the efforts to identify biomarkers through the $1M ALS Biomarker Prize were also mentioned.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail